TopFunds

Bristol-Myers Squibb Company

NYSE: BMY

Stock price

59.75 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
1
2.7
0.6
3
2
(4)
3.1
3
3.9
(4.4)
3.5
13.5%
02Free cash flow per share
0.8
1.1
2.6
3.7
4.3
5.9
6.8
5.6
6.1
6.9
6.3
23.5%
03Dividends per share
1.5
1.1
1.6
1.6
1.6
2.3
1.5
2.2
2.3
2.4
2.5
5.2%
04Dividends payout, %
1.6%
57.2%
2.6%
53.1%
77.9%
(45.2)%
62.9%
73.2%
59.1%
(54.4)%
71.5%
46.4%
PROFIT AND LOSS STATEMENT
05Revenue
16,560
19,427
20,776
22,561
26,145
42,518
46,385
46,159
45,006
48,300
48,195
11.3%
06% Change
-
-
-
-
-
-
-
-
-
-
-
11.3%
07Cost of revenue
(3,909)
(4,969)
(6,014)
(6,467)
(8,078)
(11,773)
(9,940)
(10,137)
(10,693)
(13,968)
(13,936)
13.6%
08Gross profit
12,651
14,458
14,762
16,094
18,067
30,745
36,445
36,022
34,313
34,332
34,259
10.5%
09% Margin
76.4%
74.4%
71.1%
71.3%
69.1%
72.3%
78.6%
78%
76.2%
71.1%
71.1%
73.6% A
10Operating expenses
(10,921)
(9,991)
(11,316)
(10,980)
(12,154)
(28,568)
(27,908)
(26,918)
(26,118)
(28,445)
(20,535)
6.5%
11% of Revenue
(66)%
(51.4)%
(54.5)%
(48.7)%
(46.5)%
(67.2)%
(60.2)%
(58.3)%
(58)%
(58.9)%
(42.6)%
(55.7)% A
12Operating Income
1,730
4,467
3,446
5,114
5,913
2,177
8,537
9,104
8,195
5,887
13,724
23%
13Income tax expense
(446)
(1,408)
(4,156)
(1,021)
(1,515)
(2,124)
(1,084)
(1,368)
(400)
(554)
(2,272)
17.7%
14Net Income
1,565
4,457
1,007
4,920
3,439
(9,015)
6,994
6,327
8,025
(8,948)
7,054
16.3%
15% Margin
9.5%
22.9%
4.9%
21.8%
13.2%
(21.2)%
15.1%
13.7%
17.8%
(18.5)%
14.6%
8.5% A
16Shares Outstanding
1,679
1,680
1,652
1,637
1,712
2,258
2,245
2,146
2,078
2,027
2,041
2%
17EPS Basic
1
2.7
0.6
3
2
(4)
3.2
3
3.9
(4.4)
3.5
13.6%
18EPS Diluted
1
2.7
0.6
3
2
(4)
3.1
3
3.9
(4.4)
3.5
13.5%
19EBITDA
2,637
6,464
6,116
6,788
7,377
4,929
20,118
19,221
19,366
3,168
15,230
19.2%
% Margin
15.9%
33.3%
29.4%
30.1%
28.2%
11.6%
43.4%
41.6%
43%
6.6%
31.6%
28.6% A
20Net Interest Income (expense)
(184)
(167)
(196)
(183)
(656)
(1,420)
(1,334)
(1,232)
(1,166)
(1,947)
(1,891)
26.2%
21Net Debt / EBITDA
1.6
0.4
0.4
0.1
4.8
7.5
1.6
1.6
1.5
12.9
2.4
3.2 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
2,385
4,237
5,421
6,911
12,346
14,546
13,979
9,123
11,464
10,346
10,209
15.7%
23Short-term investments
1,885
2,113
1,391
1,848
3,047
1,904
3,242
130
816
513
464
(13.1)%
24Accounts receivable
4,299
5,543
6,300
5,747
7,685
10,554
12,516
13,937
15,264
14,424
14,525
13%
25Other current assets
625
570
576
2,015
1,983
1,114
1,430
1,744
1,564
1,940
1,502
9.2%
26Inventory
1,221
1,241
1,166
1,195
4,293
2,074
2,095
2,339
2,662
2,557
2,690
8.2%
27Total Current Assets
10,415
13,704
14,854
17,716
29,354
30,192
33,262
27,273
31,770
29,780
29,390
10.9%
Non-Current Assets
28Net property, plant & equipment
4,412
4,980
5,001
5,027
6,956
6,745
6,968
7,475
8,036
8,360
9,125
7.5%
29Long-term investments
4,660
2,719
2,480
1,775
4,172
4,509
2,713
2,187
2,499
2,508
2,507
(6)%
30Other non-current assets
12,261
12,304
11,216
10,468
89,462
77,035
66,371
59,885
52,854
51,955
49,016
14.9%
31Total Non-Current Assets
21,333
20,003
18,697
17,270
100,590
88,289
76,052
69,547
63,389
62,823
60,648
11%
Total Assets
31,748
33,707
33,551
34,986
129,944
118,481
109,314
96,820
95,159
92,603
90,038
11%
LIABILITIES
Current Liabilities
32Accounts payable
1,565
1,664
2,248
1,892
2,445
2,713
2,949
3,040
3,259
3,602
3,575
8.6%
33Short-term debt
139
992
987
1,703
3,479
2,504
5,117
4,400
3,281
2,227
2,463
33.3%
34Other current liabilities
6,313
6,185
6,328
7,059
12,380
13,863
13,802
14,450
15,722
17,945
17,379
10.7%
35Total Current Liabilities
8,017
8,841
9,563
10,654
18,304
19,080
21,868
21,890
22,262
23,774
23,417
11.3%
Non-Current Liabilities
36Long-term debt
6,550
5,716
6,975
5,646
44,059
49,169
40,479
36,317
38,183
48,973
44,676
21.2%
37Other non-current liabilities
2,757
2,803
5,166
4,559
15,883
12,350
10,961
7,495
5,229
3,468
3,439
2.2%
38Total Non-Current Liabilities
9,307
8,519
12,141
10,205
59,942
61,519
51,440
43,812
43,412
52,441
48,115
17.9%
39Total Liabilities
17,324
17,360
21,704
20,859
78,246
80,599
73,308
65,702
65,674
76,215
71,532
15.2%
SHAREHOLDERS` EQUITY
40Common stock
221
221
221
221
292
292
292
292
292
292
292
2.8%
41Retained earnings / (deficit)
31,613
33,513
31,160
34,065
34,474
21,281
23,820
25,503
28,766
14,912
16,896
(6.1)%
42Accumulated other comprehensive income / (loss)
(2,468)
(2,503)
(2,289)
(2,762)
(1,520)
(1,839)
(1,268)
(1,281)
(1,546)
(1,238)
(1,523)
(4.7)%
43Noncontrolling interests
158
170
106
96
100
60
60
57
55
53
33
(14.5)%
44Total shareholders' equity
14,424
16,347
11,847
14,127
51,698
37,882
36,006
31,118
29,485
16,388
18,506
2.5%
45Total Liabilities and shareholders' Equity
31,748
33,707
33,551
34,986
129,944
118,481
109,314
96,820
95,159
92,603
90,038
11%
46Total Debt
6,689
6,708
7,962
7,349
47,538
51,673
45,596
40,717
41,464
51,200
47,139
21.6%
47Net Debt
4,304
2,471
2,541
438
35,192
37,127
31,617
31,594
30,000
40,854
36,930
24%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
1,565
4,457
1,007
4,920
3,439
(9,015)
6,994
6,327
8,025
(8,948)
7,054
16.3%
49Depreciation & amortization
376
382
789
637
1,746
10,380
10,686
10,276
9,760
9,600
4,011
26.7%
50Share-based compensation expense
235
205
199
221
441
779
583
457
518
507
553
8.9%
51Changes in working capital and other assets
(71)
(1,986)
3,280
1,288
2,584
11,908
(2,056)
(3,994)
(4,443)
14,031
2,538
-
52Net cash flows from operating activities
2,105
3,058
5,275
7,066
8,210
14,052
16,207
13,066
13,860
15,190
14,156
21%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(820)
(1,215)
(1,055)
(951)
(836)
(753)
(973)
(1,118)
(1,209)
(1,248)
(1,311)
4.8%
54Purchases of investments / marketable securities
(3,143)
(3,089)
(5,419)
(2,305)
(3,961)
(4,172)
(5,478)
(3,592)
(1,774)
(769)
(2,000)
(4.4)%
55Proceeds from maturities of marketable securities
2,794
4,809
6,398
2,379
3,976
6,409
6,775
6,629
948
1,387
2,052
(3)%
56Other investing activities
(403)
975
10
(1,123)
(9,092)
(12,343)
(862)
(2,981)
(260)
(20,722)
(2,873)
21.7%
57Net cash flows from investing activities
(1,572)
1,480
(66)
(2,000)
(9,913)
(10,859)
(538)
(1,062)
(2,295)
(21,352)
(4,132)
10.2%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
266
(50)
(2,469)
(320)
(7,300)
(1,546)
(6,287)
(8,001)
(5,155)
(106)
(128)
-
59Dividends paid, net
(2,477)
(2,547)
(2,577)
(2,613)
(2,679)
(4,075)
(4,396)
(4,634)
(4,744)
(4,863)
(5,045)
7.4%
60Debt issuance (repayments), net
(1,138)
110
991
(548)
17,653
3,928
(6,182)
(5,311)
456
10,096
(5,175)
16.4%
61Other financing activities
(275)
(166)
(22)
(54)
(53)
542
641
984
27
-
-
-
62Net cash flows from financing activities
(3,624)
(2,653)
(4,077)
(3,535)
7,621
(1,151)
(16,224)
(16,962)
(9,416)
5,127
(10,348)
11.1%
63Increase (decrease) in cash and cash equivalents
(3,186)
1,852
1,184
1,490
5,909
2,153
(657)
(4,991)
2,194
(1,172)
(137)
(27)%
64Cash and equivalents, ending balance
2,385
4,237
5,421
6,911
12,820
14,973
14,316
9,325
11,519
10,347
10,218
15.7%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
1,285
1,843
4,220
6,115
7,374
13,299
15,234
11,948
12,651
13,942
12,845
25.9%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Bristol-Myers Squibb Company (BMY) financial statements and performance

Explore Bristol-Myers Squibb Company (BMY) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.